Researchers Jorg van Loosdregt

Jorg van Loosdregt

Associate Professor

Strategic program(s):

Biography

Jorg van Loosdregt (1981) obtained his PhD at the Molecular Immunology laboratory, University Medical Center Utrecht, The Netherlands. Here, he studied the regulation of the transcription factor FOXP3, which is crucial for both the differentiation and function of Regulatory T cells, and therefore for maintaining immune homeostasis. After completing his PhD program in 2011 (cum laude) Jorg moved to the Department of Translational Research, at the Sanford-Burnham Medical Institute in San Diego, USA, on a fellowship from the Dutch Arthritis Foundation. Here he investigated the role of autophagy in orchestrating effector T cell responses, with a focus on rheumatoid arthritis. Since December 2013 van Loosdregt is working in the laboratory for translational immunology (LTI) and Center for Molecular Medicine (CMM) where he is supported by a VENI fellowship. Here he uses a translational approach to study the molecular pathways that are deregulated in autoimmune diseases with the aim of identifying novel therapeutic strategies to treat these diseases.

Strategic program(s):

Contact

jloosdre@umcutrecht.nl

Pure profile

Research groups

Translational immunology

Research aim

It is our goal to improve the diagnosis and treatment of immune-related diseases with a focus on Juvenile Idiopathic Arthritis

Go to group

Pediatric immunology team

Research aim

The pediatric immunology team focuses on the under-explored research field of immune response modification for the prevention of immune-driven diseases. The goal of our research is to develop interventions that can prevent disease manifestations.

Go to group

Recent publications

All publications

m⁶A Reader YTHDC1 Impairs Respiratory Syncytial Virus Infection by Downregulating Membrane CX3CR1 Expression Lucas W. Picavet, Ellen C.N. van Vroonhoven, Rianne C. Scholman, Yesper T.H. Smits, Rupa Banerjee, Sjanna B. Besteman, Mattheus C. Viveen, Michiel M. van der Vlist, Marvin E. Tanenbaum, Robert J. Lebbink, Sebastiaan J. Vastert, Jorg van Loosdregt
Viruses, 2024, vol. 16

CBP/P300 Inhibition Impairs CD4+ T Cell Activation Lucas Wilhelmus Picavet, Anoushka A K Samat, Jorg Calis, Lotte Nijhuis, Rianne Scholman, Michal Mokry, David F Tough, Rabinder K Prinjha, Sebastiaan J Vastert, Jorg van Loosdregt
Biomedicines, 2024, vol. 12

N⁶-Methyladenosine Directly Regulates CD40L Expression in CD4⁺ T Lymphocytes Ellen C.N. van Vroonhoven, Lucas W. Picavet, Rianne C. Scholman, Noortje A.M. van den Dungen, Michal Mokry, Anouk Evers, Robert J. Lebbink, Jorg J.A. Calis, Sebastiaan J. Vastert, Jorg van Loosdregt
Biology, 2023, vol. 12

Conventional dendritic cells type 1 are strongly enriched, quiescent and relatively tolerogenic in local inflammatory arthritis Arjan Boltjes, Anoushka Ashok Kumar Samat, Maud Plantinga, Michal Mokry, Bas Castelijns, Joost F. Swart, Sebastiaan J. Vastert, Menno Creyghton, Stefan Nierkens, Jorg van Loosdregt, Femke van Wijk
Frontiers in Immunology, 2023, vol. 13

The clinical and experimental treatment of Juvenile Idiopathic Arthritis L Nijhuis, J F Swart, B J Prakken, J V Loosdregt, S J Vastert
Clinical and Experimental Immunology, 2023, vol. 213, p.276-287

Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition Janneke G C Peeters, Arjan Boltjes, Rianne C Scholman, Stephin J Vervoort, Paul J Coffer, Michal Mokry, Sebastiaan J Vastert, Femke van Wijk, Jorg van Loosdregt
Rheumatology (Oxford, England), 2023, vol. 62, p.2887-2897

Fellowships & Awards

2020: Jeffrey Modell Foundation C.H.I.L.D.R.E.N! Research Program grant